United States Radioimmunoassay Market Size, Share, Growth, Trends, Industry Analysis & Forecast 2026–2034

To remain competitive, RIA manufacturers must focus on specialized applications where the technique offers meaningful analytical advantages, established validation, or suitability for particular research requirements.

Regulatory Requirements and Radioactive Material Management

Radioimmunoassay requires laboratories to handle radioactive materials responsibly, creating additional operational and compliance requirements.

Facilities using radioactive reagents must establish appropriate procedures for storage, handling, contamination prevention, staff training, monitoring, and waste disposal. Applicable requirements depend on the radioactive isotope, material, and specific laboratory activity.

The U.S. Nuclear Regulatory Commission regulates radioactive materials under its jurisdiction, while certain materials and activities fall under state regulatory programs or other applicable authorities.

Additionally, laboratories conducting patient testing must follow relevant clinical laboratory quality standards. The Food and Drug Administration oversees applicable medical products and diagnostic tests.

These requirements can increase operational expenses, particularly for smaller laboratories. Competition from nonradioactive technologies further influences purchasing decisions and limits the adoption of conventional RIA systems.

United States Radioimmunoassay Market Trends and Recent Developments

The U.S. diagnostic industry is experiencing continued development in immunoassay sensitivity, laboratory automation, clinical chemistry, and specialized biomarker testing.

Recent industry developments include:

• Access Cortisol – Beckman Coulter (2025): The FDA issued a 510(k) clearance decision on March 5, 2025, for Access Cortisol on the DxC 500i Clinical Analyzer, supporting cortisol testing in clinical laboratories.
• SPEAR UltraDetect Immunoassays – Spear Bio (2025): Launched on July 25, 2025, this ultrasensitive immunoassay solution initially included four neurological biomarkers: pTau231, pTau217, GFAP, and NfL. It represents an alternative immunoassay technology rather than a radioimmunoassay.
• Estrone RIA Kit – Beckman Coulter (2025–2026): The company issued recall notices concerning specific Estrone RIA kit lots following a manufacturing-material issue. These actions represent product-quality measures rather than new product launches.
• Elecsys Calcitonin – Roche Diagnostics (2026): The FDA issued a 510(k) clearance decision on April 24, 2026, for this assay, which measures calcitonin in clinical testing.
• cobas c 703 – Roche Diagnostics (2026): FDA-cleared on March 30, 2026, this clinical chemistry analyzer offers throughput of up to 2,000 tests per hour, supporting high-volume laboratory workflows.
• cobas ISE neo – Roche Diagnostics (2026): Cleared alongside the cobas c 703, this analytical unit supports electrolyte testing at throughput levels of up to 1,800 tests per hour.

These developments demonstrate broader improvements in clinical laboratory testing, automation, and immunoassay technologies. However, not all represent direct RIA product launches.

Regional Analysis of the United States Radioimmunoassay Market

California

California represents a significant regional market because of its extensive biotechnology industry, academic institutions, and advanced medical research facilities. With approximately 39.4 million residents in 2024, the state has substantial demand for healthcare services and laboratory diagnostics.

Universities, biotechnology companies, and specialized laboratories support applications involving hormone measurement, biomarker analysis, and pharmaceutical research. Nevertheless, radioactive-material handling requirements and competition from automated nonradioactive immunoassays remain challenges.

Texas

Texas is an important market supported by expanding healthcare infrastructure, major medical centers, and growing life sciences research activities. Its population reached approximately 31.3 million in July 2024.

Houston, Dallas, Austin, and San Antonio have hospitals, universities, and research organizations investigating endocrine disorders, metabolic conditions, and pharmaceutical development. These institutions create opportunities for specialized RIA-based testing and research applications.

New York

New York maintains a strong position because of its concentration of academic medical centers, hospitals, pharmaceutical companies, and biomedical research laboratories.

With approximately 19.9 million residents in July 2024, the state supports significant healthcare and specialized diagnostic activity. Research into hormone regulation, metabolic disorders, drug interactions, and disease biomarkers contributes to demand for sensitive analytical technologies.

Florida

Florida offers growth opportunities through its expanding healthcare network, older population, and increasing demand for specialized diagnostic testing. The state had approximately 23.4 million residents in July 2024.